GT Biopharma's TriKE™ Interim Clinical Trial Results Presented At Innate Killer Summit 2021PRNewsWire • 03/29/21
GT Biopharma's GTB-3550 Cuts Bone Marrow Blasts In High-Risk Patients With Hematological MalignanciesBenzinga • 03/17/21
GT Biopharma Announces Pricing of $23,650,000 Public Offering and Uplisting to The Nasdaq Capital MarketBusiness Wire • 02/11/21
GT BIOPHARMA ANNOUNCES FDA DATA - GTB-3550 TriKE™ REDUCES CANCER CELLS BY 61.7% FOR A HIGH-RISK MYELODYSPLASTIC SYNDROMES (HR-MDS) PATIENTPRNewsWire • 12/21/20